The effects of melatonin in the treatment of delirium
- Conditions
- acute confusionpsychosis10012221
- Registration Number
- NL-OMON32448
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 702
Inclusion Criteria
1] Age 65 years or older
2] Acute hospital admission at medical ward
3] Patients diagnosed with delirium for which anti-psychotic therapy is needed.
4] Patients must be willing and medically able to receive therapy according to the protocol for the duration of the study
5] Written informed consent must be obtained
Exclusion Criteria
1] Patients on medication that can*t speak or understand Dutch
2] Patients diagnosed with delirium who have received anti-psychotics longer than 24 hours.
3] Patients with a clinical diagnosis of hypoactive delirium
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p> Evaluate possible differences in duration of delirium between the<br /><br>anti-psychotics + melatonin group and the anti-psychotics + placebo group. </p><br>
- Secondary Outcome Measures
Name Time Method